Nanoplatforms Based Cancers Therapy 2.0
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 7772
Special Issue Editor
Interests: photodynamic therapy; two-photon excitation; cancer targeting
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the previous release, “Nanoplatforms Based Cancers Therapy” (https://www.mdpi.com/journal/cancers/special_issues/Nanoplatforms_Cancers).
Nanomedicine is now considered a hopeful strategy with which to efficiently target cancer cells and deliver, more specifically, the molecule of interest to the area to imaging and treatment. A large variety of biocompatible nanoparticles have been produced in the last few years to carry and protect from biological barriers those molecules that are designed for imaging or therapy. In addition, grafting with targeting moieties allows the tumor area to be better addressed. Finally, a stimuli response system such as laser, temperature or ultrasounds to deliver the cargo to the selected site, can add a supplementary dimension to the conception of high-potency controlled nanodevices.
In this Special Issue, we will focus on novel nanoplatforms for the therapy and/or imaging of cancers. The therapeutic strategy could be drug or nucleic acid delivery, or photodynamic, photothermal or ultrasounds therapy; in addition, surface ligands anchoring could be a strong advantage to efficiently introduce the nanoplatforms to the tumor area and, more particularly, to cancer cells. This Special Issue aims to highlight novel nanodevices with cancer applications.
Dr. Magali Gary-Bobo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoplatforms
- cancer therapy
- imaging
- targeting
- controlled delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
